Search Results for "Tudorza Pressair"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Tudorza Pressair. Results 11 to 12 of 12 total matches.
See also: aclidinium, aclidinium bromide
Olodaterol (Striverdi Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
/inhalation MDI (28, 60 inh/unit) 5 mcg once/day 297.80
Aclidinium – Tudorza Pressair (Actavis) 400 mcg ...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD). It is
not approved for treatment of acute exacerbations of
COPD or for treatment of asthma. Olodaterol is the third
long-acting beta2-agonist to be approved by the FDA
for once-daily use; indacaterol (Arcapta Neohaler),
which is available as a single agent, and vilanterol,
which is available only in fixed-dose combinations
with the...
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
Antimuscarinic Agents (LAMAs)
Aclidinium – Tudorza Pressair (Covis) 400 mcg/inh DPI (30, 60 inh/unit) 1 inh bid ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction